1YBelow half the group
Rank 38 of 63 funds
Return +17.62%
1Y returns of 63 funds in the Health Care group, sorted from highest to lowest. This fund ranks 38No. 1 is SCBGENOME(E) +62.13%
BCAP NEXT GEN Health Fund
Shows where this fund stands in its group. Not investment advice · Data as of 3 Nov 2026
BCAP-XHEALTH is a fund of funds that puts 99.17% into units of other funds, spread across several funds
This fundBCAP-XHEALTHThis fund's manager selects the funds and adjusts their weights. The funds it holds also charge their own fees
Revolution Medicines RVMD2.03%
Twist Bioscience TWSTOver the past year it trailed half its group; over 5 years it returned −6.33% per year (Below half the group)
No. 1 is SCBGENOME(E) +62.13%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 3 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | 5Y | MAX |
|---|---|---|---|---|---|---|---|---|---|
| +20.73% | +2.79% | +4.39% | +0.22% | +7.28% | +22.69% | +17.62% | +27.13% | −27.90% | −25.24% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan |
|---|
Largest drawdown in the selected period −52.44% Previous peak 5 Aug 2021 (NAV 11.5642) → Trough 8 Apr 2025 (NAV 5.4996) · Not back to the previous peak as of 30 Oct 2026
Currently −35.40% from the peak NAV of 11.5642 (5 Aug 2021)
Over 5 years, BCAP-XHEALTH returned -0.29 per unit of volatility, ranking 27 of 33 funds · The highest is FP HCARE-A (0.43)
กองทุนมีนโยบายการลงทุนในหน่วยลงทุนของกองทุนรวมตราสารทุนต่างประเทศ โดยกองทุนปลายทางมีการกระจายการลงทุนในหลักทรัพย์หรือตราสารของบริษัทที่ได้ประโยชน์จากการประกอบธุรกิจที่เกี่ยวข้องกับสุขภาพรูปแบบใหม่ เช่น Gene Therapy, Telemedicine, Healthcare IT Infrastructure เป็นต้น ทั้งน… Its largest holdings are JAN HND HRZN BIOTECH-IU2 USD (JHHBIU2 LX) 34.19% · ARK GENOMIC REVOLUTION ETF (ARKG US) 18.62% · UBS LUX DIG HEALTH EQ-EB USD (CSGDEBU LX) 16.25% (fact sheet 30 Sep 2026)
Risk level 6 of 8 (High risk). Since 14 May 2021, its NAV has fallen as much as −52.44% from its peak.
Actual total expense ratio (TER) 1.23% a year, against a ceiling of 2.68%. Management fee 1.07%. Front-end fee 1.07%. Back-end fee 0.00%. (Fact sheet 31 Aug 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Top 5 funds, as disclosed in the AMC fact sheet · The stocks these funds hold are shown below · This fund's performance therefore depends on the funds it holds
10x Genomics TXG1.87%
Tempus AI Inc Class A common… TEM1.66%
Praxis Precision PRAX1.62%
BridgeBio Pharma BBIO1.37%
argenx ARGX1.33%
Gilead Sciences GILD1.32%
Travere Therapeutics TVTX1.22%
Eli Lilly and Co LLY1.21%Revolution Medicines RVMDBiotech company that develops drugs for RAS-driven cancers, such as pancreatic cancer
Twist Bioscience TWSTMakes synthetic DNA on silicon chips for drug and genetics research
10x Genomics TXGMakes single-cell analysis instruments and reagents for biology research
Praxis Precision PRAXBiotech company that develops drugs for neurological conditions such as epilepsy and tremor
BridgeBio Pharma BBIODevelops drugs for genetic diseases, including Attruby for the heart disease ATTR-CM
argenx ARGXEuropean biotech that makes Vyvgart to treat autoimmune diseases such as myasthenia gravis
Gilead Sciences GILDA US drug company making HIV treatment and prevention drugs, hepatitis drugs and cancer drugs
Travere Therapeutics TVTXDevelops drugs for rare diseases, including Filspari for IgA nephropathy
Eli Lilly and Co LLYDiabetes and weight-loss drugs
Based on each ETF's actual share of the fund's value · Weighted by each fund held × the stocks that fund holds, covering 64% of the money invested in other funds. Uses each fund's top 10, so figures are a minimum · JHHBIU2 LX as of 31 Aug 2026 · ARK Genomic Revolution as of 22 Oct 2026 · Xtrackers MSCI World Health Care UCITS ETF 1 as of 27 Oct 2026 · Illustrations are for explanation only, not individual stock recommendations
No. 1 is SCBGENOME(E) +21.97% per year
No. 1 is FP HCARE-A +6.61% per year
| Feb |
|---|
| Mar |
|---|
| Apr |
|---|
| May |
|---|
| Jun |
|---|
| Jul |
|---|
| Aug |
|---|
| Sep |
|---|
| Oct |
|---|
| Nov |
|---|
| Dec |
|---|
| Full year |
|---|
| 2026 | +1.4 | −1.3 | −3.2 | +1.6 | +2.5 | +11.6 | −1.9 | +8.2 | +0.8 | +0.2 | · | · | +20.7* |
| 2025 | +6.2 | −0.6 | −7.6 | −0.4 | −3.6 | +3.4 | −0.4 | +3.3 | +2.9 | +2.7 | +2.8 | −6.5 | +1.1 |
| 2024 | −2.4 | +6.0 | +0.3 | −6.0 | +1.5 | +0.3 | +1.2 | −2.1 | −6.5 | −0.0 | +4.7 | −7.0 | −10.4 |
| 2023 | +4.0 | −0.0 | −3.5 | +0.5 | −0.7 | +4.7 | +0.9 | −6.3 | −3.2 | −10.0 | +7.5 | +7.4 | −0.4 |
| 2022 | −15.0 | −3.5 | +2.3 | −12.0 | −3.2 | +4.6 | +11.5 | −5.6 | −5.2 | +5.6 | −2.2 | −6.4 | −27.9 |
Minimum first purchase 500 THB, subsequent purchases 500 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+3
Hedged at the manager's discretion